Guideline

NMG Acquires Mason Resources’ Lac Guéret Graphite Deposit/Uatnan Mining Project – One of the World’s Largest Graphite Projects in Development

Retrieved on: 
Monday, January 22, 2024

The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, market or other relevant issues.

Key Points: 
  • The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, market or other relevant issues.
  • There is no certainty that any part of a Mineral Resource will ever be converted into Mineral Reserves.
  • The Mineral Resources presented here were estimated with a block size of 3mE x 3mN x 3mZ.
  • NMG is projected to become the largest natural graphite producer in North America, fully integrated from ore to anode material, and with demonstrated sustainability performance.

ChromaCode Announces Publication of New Study Demonstrating the Superior Performance of its HDPCR NSCLC Assay Compared to NGS with Low Sample Input

Retrieved on: 
Friday, January 26, 2024

ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.

Key Points: 
  • ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.
  • The HDPCR NSCLC Panel is an ideal test for National Comprehensive Cancer Network (NCCN) guideline directed clinically relevant variants.
  • "We have leveraged our HDPCR technology to build a rapid and cost-effective first line assay in NSCLC, covering 99.6% of prevalent NCCN variants.
  • The findings suggest that HDPCR emerges as a precise and efficient approach for identifying clinically relevant NSCLC mutations, even with low nucleotide input and quality.

Fidelis Sustainability Distribution and Biofidelity Collaborate to Bring Rapid Precision Genomic Testing to Veterans Administration (VA) Customers

Retrieved on: 
Wednesday, January 24, 2024

RESEARCH TRIANGLE PARK, N.C. and CARSON CITY, Nev., Jan. 24, 2024 /PRNewswire/ -- Biofidelity and Fidelis Sustainability Distribution (Fidelis) today announced that they have entered into an agreement to make ASPYRE®-Lung available to VA Medical Centers and active military institutions across the US.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C. and CARSON CITY, Nev., Jan. 24, 2024 /PRNewswire/ -- Biofidelity and Fidelis Sustainability Distribution (Fidelis) today announced that they have entered into an agreement to make ASPYRE®-Lung available to VA Medical Centers and active military institutions across the US.
  • The agreement aims to improve non-small cell lung cancer (NSCLC) patient treatment access, affordability and outcomes by making ASPYRE-Lung readily available to veterans, active military personnel and their families.
  • "ASPYRE-Lung addresses a critical need for the people we serve with NSCLC," said Timothy Buxton, Fidelis General Manager.
  • "Clinicians need better tools to make faster, more informed decisions for their patients," said Wendy Levin, MD, MS Biofidelity Chief Medical Officer.

INVICTA by Jetaire Selected by Canadian North and Nolinor Aviation as Preferred Ignition Mitigation Solution

Retrieved on: 
Tuesday, January 23, 2024

FAYETTEVILLE, Ga., Jan. 23, 2024 /PRNewswire/ -- Canadian North and Nolinor Aviation, two prominent Canadian airline operators, have recently selected INVICTA by Jetaire as their preferred ignition mitigation means and method of compliance to FAA airworthiness directive 2020-18-13. This strategic decision underscores both operators' commitment to meeting regulatory requirements for fuel tank safety well ahead of the upcoming 2026 mandatory timeline.

Key Points: 
  • FAYETTEVILLE, Ga., Jan. 23, 2024 /PRNewswire/ -- Canadian North and Nolinor Aviation, two prominent Canadian airline operators, have recently selected INVICTA by Jetaire as their preferred ignition mitigation means and method of compliance to FAA airworthiness directive 2020-18-13.
  • INVICTA by Jetaire is a cutting-edge ignition mitigation system that has garnered acclaim for its advanced technology and proven effectiveness in preventing ignition sources in aircraft fuel tanks.
  • Its adoption by Canadian North and Nolinor Aviation reflects their dedication to staying at the forefront of safety and innovation in the aviation industry.
  • The adoption of INVICTA by Canadian North and Nolinor Aviation marks a significant step in bolstering aviation safety and compliance within the Canadian aviation industry.

New Report: Economic Fears Driving Retirees Back to Work

Retrieved on: 
Monday, January 22, 2024

COLUMBUS, Ohio, Jan. 22, 2024 /PRNewswire/ -- This year, more Americans will turn 65 years old than at any point in history, with roughly 12,000 people a day reaching the age most target for retirement. A new survey from the Nationwide Retirement Institute® reveals that many adults in this age range are not as financially comfortable as they expected to be at this stage of life.

Key Points: 
  • There is a significant gap between the realities of current retirees and the expectations of adults ages 60-65 who are still working.
  • They expect to spend 42% of their income on food, housing, and other basic expenses, while retirees actually spend 53% on those expenses.
  • Retiring ahead of schedule: 64% of current retirees stopped working earlier than planned, which can reduce important years to save for retirement.
  • If Congress does not take action, future retirees can expect a 23% cut in benefits, according to the Social Security Administration .

APS secondary alternators meet Mercedes Body & Equipment Guideline criteria for newer Sprinter models

Retrieved on: 
Monday, January 22, 2024

Before releasing any new products to the market, APS tests them to industry standards for durability to ensure they meet our threshold for superior quality, reliability and performance.

Key Points: 
  • Before releasing any new products to the market, APS tests them to industry standards for durability to ensure they meet our threshold for superior quality, reliability and performance.
  • This rigorous process helps APS feel confident in their real-world performance because of how meticulous they are behind the scenes during their development.
  • "Before APS releases a product, we make sure that it's going to perform like we say it will," said APS President & CEO Amy Lank.
  • To discuss configurations available, contact APS' Commercial & Fleet department at (866) 446-8878 (US only) or +1-563-323-7994 (international).

Built In Honors Tinuiti in Its 2024 Best Place To Work Awards List

Retrieved on: 
Wednesday, January 17, 2024

NEW YORK, Jan. 17, 2024 /PRNewswire/ -- Tinuiti, the largest independent performance marketing firm across Streaming TV, Google, Meta, and Amazon, has been honored with the "Best Places to Work" award by Built In, earning both Remote Best Places to Work and Remote Best Large Places to Work designations and landing among 18 city-specific Best Places to Work lists.

Key Points: 
  • NEW YORK, Jan. 17, 2024 /PRNewswire/ -- Tinuiti , the largest independent performance marketing firm across Streaming TV, Google, Meta, and Amazon, has been honored with the "Best Places to Work" award by Built In, earning both Remote Best Places to Work and Remote Best Large Places to Work designations and landing among 18 city-specific Best Places to Work lists.
  • Built In's Best Places to Work program is distinct because it does not follow a typical nomination process, instead the program uses an algorithm to select winners, honoring only those companies who align awards packages with employees' top priorities.
  • Last year, Tinuiti formally launched Project Connection, a program designed to foster connection and collaboration in an out-of-office workplace.
  • Collaboration, bringing people together for meaningful work, led to impactful mentorships, in-person team bonding, and ongoing learning and development.

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-17 January 2024

Retrieved on: 
Friday, January 19, 2024

CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

Key Points: 


CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Retrieved on: 
Tuesday, January 9, 2024

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.

Key Points: 
  • SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.
  • Among the guidance includes:
    All patients with a current or previous diagnosis of invasive breast cancer ≤ 65 years should be offered BRCA1/2 testing.
  • Patients undergoing genetic testing should be given sufficient information before testing to provide informed consent.
  • “ASCO-SSO’s guideline update is an important step forward in advancing the use of genomics in clinical care for patients with breast cancer,” said Shelly Cummings, Vice President of Oncology Medical Affairs, Myriad Genetics.

BeniComp to Offer GRAIL’s Multi-Cancer Early Detection Test for Employee Health Screening

Retrieved on: 
Thursday, January 11, 2024

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and BeniComp, a customized health plan provider, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test, to eligible patients initially through BeniComp Select members.

Key Points: 
  • GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and BeniComp, a customized health plan provider, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test, to eligible patients initially through BeniComp Select members.
  • This partnership underscores BeniComp’s commitment to proactive and preventive health management, enabling an even broader reach of their transformative health insurance products.
  • "Integrating GRAIL's groundbreaking multi-cancer early detection technology into BeniComp’s plans is a step forward in our mission to impact the root cause of diseases and high costs," said Steve Presser, President of BeniComp.
  • “We are pleased to collaborate with payors like BeniComp that share in our commitment to early detection, when outcomes are more likely to be favorable.”